Novavax to produce 2bn COVID-19 vaccine doses in 2022


Novavax, vaccine developer, says at least two billion doses of its COVID-19 vaccine will be available in 2022.

In June, Novavax said its vaccine is more than 90 percent effective in a late-stage US-based clinical trial.

The company said it will apply for emergency use of its vaccine before December.

According to the Chief commercial officer of Novavax, John Trizzino,“We’re already engaging in conversations about incremental procurement for the second half of 2022, as well as early 2023, especially given current vaccination rates around the globe,”

Leave a Reply

Your email address will not be published. Required fields are marked *